Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Allergy Asthma Immunol ; 132(1): 13-20, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37652232

ABSTRACT

OBJECTIVE: To evaluate the current evidence, its limitations, and future research directions for the use of biologics in pediatric asthma, with a particular focus on the potential use of biologics to prevent pediatric asthma and equity issues in access to biologic treatment and research participation. DATA SOURCES: PubMed articles about the use of biologics in pediatric asthma were searched up to May 2023. STUDY SELECTIONS: Recent (2019-2023) original research articles and reviews were prioritized. RESULTS: Although there are now 5 U.S. Food and Drug Administration-approved biologics for use in pediatric asthma, there are important knowledge gaps that ongoing research seeks to address, which include (1) the long-term efficacy and safety of using biologics in children, (2) the comparative efficacy of different biologics, (3) multi-omics-based classification of asthma endotypes and phenotypes in children to find potential new therapeutic targets and enable identification and validation of new biomarkers that may predict and help monitor response to treatment, and (4) whether starting biologics in early childhood can modify the natural history of asthma and potentially prevent asthma development. SUMMARY: To promote equitable access to biologics and optimize asthma outcomes, future research should recruit patients across the full spectrum of socioeconomic and racial/ethnic backgrounds. Large-scale national and international collaborations between asthma researchers and clinicians are also necessary to fully understand the role of biologics in pediatric asthma.


Subject(s)
Anti-Asthmatic Agents , Asthma , Biological Products , Child , Humans , Child, Preschool , Anti-Asthmatic Agents/therapeutic use , Biological Products/therapeutic use , Asthma/drug therapy , Asthma/chemically induced , Biomarkers , Health Services Accessibility
2.
J Med Humanit ; 42(4): 641-657, 2021 Dec.
Article in English | MEDLINE | ID: mdl-31981016

ABSTRACT

This paper describes a pilot study of a new model for narrative medicine training, "community-based participatory narrative medicine" (CBPNM), which centers on shared narrative work between healthcare trainees and patients. Nine medical students and eight patients participated in one of two, five-week-long pilot workshop series. A case study of participants' experiences of the workshop series identified three major themes: (1) the reciprocal and collaborative nature of participants' relationships; (2) the interplay between self-reflection and receiving feedback from others; and (3) the clinical and pedagogical implications of the CBPNM model. Principles and proposed outcomes of the CBPNM model are presented.


Subject(s)
HIV Infections , Narrative Medicine , Students, Medical , Curriculum , Delivery of Health Care , Humans , Pilot Projects
3.
Drugs R D ; 20(4): 319-330, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32960413

ABSTRACT

BACKGROUND: Subacute cutaneous lupus erythematosus (SCLE) lacks consensus diagnostic criteria and the pathogenesis is poorly understood. There are increasing reports of SCLE induced by monoclonal antibodies (mAbs), but there are limited data on the aetiology, clinical characteristics and natural course of this disease. METHODS: We devised a set of diagnostic criteria for SCLE in collaboration with a multinational, multispecialty panel. This systematic review employed a two-layered search strategy of five databases for cases of mAb-induced SCLE (PROSPERO registered protocol CRD42019116521). To explore the relationship between relative mAb use and the number of SCLE cases reported, the estimated number of mAb users was modelled from 2013 to 2018 global commercial data and estimated annual therapy costs. RESULTS: From 40 papers, we identified 52 cases of mAb-induced SCLE, occurring in a cohort that was 73% female and with a median age of 61 years. Fifty percent of cases were induced by anti-tumour necrosis factor (TNF)-ɑ agents. A median of three drug doses preceded SCLE onset and the lesions lasted a median of 7 weeks after drug cessation. Oral and topical corticosteroids were most frequently used. Of the licensed mAbs, adalimumab, denosumab, rituximab, etanercept and infliximab were calculated to have the highest relative number of yearly users based on global sales data. Comparing the number of mAb-induced SCLE cases with estimated yearly users, the checkpoint inhibitors pembrolizumab and nivolumab showed strikingly high rates of SCLE relative to their global use, but ipilimumab did not. CONCLUSION: We present the first systematic review characterising mAb-induced SCLE with respect to triggers, clinical signs, laboratory findings, prognosis and treatment approaches. We identify elevated rates associated with the use of checkpoint inhibitors and anti-TNFɑ agents.


Subject(s)
Antibodies, Monoclonal/adverse effects , Immunologic Factors/adverse effects , Lupus Erythematosus, Cutaneous/chemically induced , Lupus Erythematosus, Cutaneous/therapy , Antibodies, Monoclonal/economics , Antibodies, Monoclonal/therapeutic use , Humans , Immunologic Factors/economics , Immunologic Factors/therapeutic use , International Cooperation , Lupus Erythematosus, Cutaneous/epidemiology , Prognosis , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...